ArticleBiosensors & bioelectronics: X2026
Recent advances in smart contact lenses.
Article in Biosensors & bioelectronics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The growing demand for healthcare services and recent advances in materials and biosensing technologies have accelerated the development of point-of-care (POC) diagnostics, with smart contact lenses (SmCLs) emerging as a promising platform. This review systematically evaluates the role of tear fluid as a noninvasive diagnostic medium, highlighting its biochemical composition and challenges in sample collection. We examine the design parameters essential for functional SmCLs, including biocompatibility, oxygen permeability, wettability, and mechanical properties, which collectively determine long-term comfort and device performance. SmCLs can significantly improve the bioavailability of drug delivery while addressing the limitations of traditional ocular treatments, such as the rapid dissipation of eye medications through the nasolacrimal duct. Furthermore, the potential of SmCLs in disease diagnosis through chemical and physical biomarker detection is highlighted, showcasing their ability to monitor glucose levels and intraocular pressure in real-time. Overall, current evidence supports SmCLs as multifunctional devices capable of combining diagnostics and therapy in real time. However, large-scale validation studies are required to establish clinical accuracy, patient adherence, and cost-effectiveness. This review concludes that SmCLs represents an innovative direction in personalized healthcare, integrating materials science, biosensing, and drug delivery for noninvasive, continuous health monitoring of ocular and system diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.